BeOne Medicines annual operating income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Operating Income Growth & History (ONC)
BeOne Medicines's operating income was $447.1M for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $447.1M | $1.02B | — |
| 2024 | 2024-12-31 | −$568.2M | $639.5M | — |
| 2023 | 2023-12-31 | −$1.21B | $581.9M | — |
| 2022 | 2022-12-31 | −$1.79B | −$350.9M | — |
| 2021 | 2021-12-31 | −$1.44B | $218.9M | — |
| 2020 | 2020-12-31 | −$1.66B | −$697.8M | — |
| 2019 | 2019-12-31 | −$959.9M | −$254.1M | — |
| 2018 | 2018-12-31 | −$705.8M | −$607.3M | — |
| 2017 | 2017-12-31 | −$98.5M | $18.6M | — |
| 2016 | 2016-12-31 | −$117.1M | −$60.3M | — |
| 2015 | 2015-12-31 | −$56.7M | −$41.0M | — |
| 2014 | 2014-12-31 | −$15.8M | — | — |
BeOne Medicines quarterly operating income
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $325.0M | $237.2M | +269.85% |
| Q1 2026 | 2026-03-31 | $249.9M | $238.8M | +2150.96% |
| Q4 2025 | 2025-12-31 | $185.0M | $264.5M | — |
| Q3 2025 | 2025-09-30 | $163.1M | $283.4M | — |
| Q2 2025 | 2025-06-30 | $87.9M | $195.0M | — |
| Q1 2025 | 2025-03-31 | $11.1M | $272.4M | — |
| Q4 2024 | 2024-12-31 | −$79.4M | $304.4M | — |
| Q3 2024 | 2024-09-30 | −$120.3M | $13.7M | — |
| Q2 2024 | 2024-06-30 | −$107.2M | $211.6M | — |
| Q1 2024 | 2024-03-31 | −$261.3M | $109.9M | — |
| Q4 2023 | 2023-12-31 | −$383.8M | $84.8M | — |
| Q3 2023 | 2023-09-30 | −$134.0M | $304.4M | — |
| Q2 2023 | 2023-06-30 | −$318.7M | $120.7M | — |
| Q1 2023 | 2023-03-31 | −$371.3M | $72.0M | — |
| Q4 2022 | 2022-12-31 | −$468.6M | $103.1M | — |
| Q3 2022 | 2022-09-30 | −$438.4M | $24.0M | — |
| Q2 2022 | 2022-06-30 | −$439.4M | $35.4M | — |
| Q1 2022 | 2022-03-31 | −$443.3M | −$513.5M | — |
| Q4 2021 | 2021-12-31 | −$571.7M | −$86.8M | — |
| Q3 2021 | 2021-09-30 | −$462.3M | −$22.2M | — |
| Q2 2021 | 2021-06-30 | −$474.8M | −$116.0M | — |
| Q1 2021 | 2021-03-31 | $70.2M | $443.9M | — |
| Q4 2020 | 2020-12-31 | −$484.9M | −$96.9M | — |
| Q3 2020 | 2020-09-30 | −$440.1M | −$127.9M | — |
| Q2 2020 | 2020-06-30 | −$358.9M | −$273.0M | — |
| Q1 2020 | 2020-03-31 | −$373.8M | −$200.0M | — |
| Q4 2019 | 2019-12-31 | −$388.0M | −$107.2M | — |
| Q3 2019 | 2019-09-30 | −$312.3M | −$161.2M | — |
| Q2 2019 | 2019-06-30 | −$85.8M | $77.2M | — |
| Q1 2019 | 2019-03-31 | −$173.8M | −$62.9M | — |
| Q4 2018 | 2018-12-31 | −$280.8M | −$177.0M | — |
| Q3 2018 | 2018-09-30 | −$151.1M | −$266.0M | — |
| Q2 2018 | 2018-06-30 | −$163.1M | −$105.0M | — |
| Q1 2018 | 2018-03-31 | −$110.8M | −$59.3M | — |
| Q4 2017 | 2017-12-31 | −$103.8M | −$66.5M | — |
| Q3 2017 | 2017-09-30 | $114.9M | $149.7M | — |
| Q2 2017 | 2017-06-30 | −$58.0M | −$33.4M | — |
| Q1 2017 | 2017-03-31 | −$51.5M | −$31.2M | — |
| Q4 2016 | 2016-12-31 | −$37.3M | −$10.9M | — |
| Q3 2016 | 2016-09-30 | −$34.8M | −$20.8M | — |
| Q2 2016 | 2016-06-30 | −$24.6M | −$18.1M | — |
| Q1 2016 | 2016-03-31 | −$20.3M | −$10.5M | — |
| Q4 2015 | 2015-12-31 | −$26.4M | — | — |
| Q3 2015 | 2015-09-30 | −$14.0M | — | — |
| Q2 2015 | 2015-06-30 | −$6.6M | — | — |
| Q1 2015 | 2015-03-31 | −$9.8M | — | — |
BeOne Medicines operating income trends
Over the last five fiscal years, BeOne Medicines's operating income increased from −$1.66B to $447.1M, a change of $2.10B. The latest reported quarter, Q2 2026, shows $325.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗Community posts
BeOne’s initial clinical results support planned late-stage studies
BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% ...
